BSE filing, NSE: SAIPARENT. Summary written from the filing by ALFA Finder's alert engine.
Sai Parenterals Ltd: key numbers
- Share price
- ₹484.05
- Market cap
- ₹2,138 Cr
- Revenue (annual)
- ₹381.0 Cr
- Net profit (annual)
- ₹14.26 Cr
- P/E (TTM)
- 103.0×Sector 46.1×
- Promoter holding
- 51.16%+0.00% QoQ
- FII holding
- 2.85%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sai Parenterals Ltd
All →Sai Parenterals Board Meeting Date
Sai Parenterals Ltd notified a Board Meeting on 1 Nov 2026 to approve unaudited Q2/H1 FY27 results. No financial figures or decisions are reported yet.
Sai Parenterals Acquisition Worth ₹15 Cr
Sai Parenterals Limited has acquired a 60% stake in Prathyak Laboratories Private Limited for ₹15 Crore. This acquisition provides an operational R&D facility in Hyderabad.
- Value
- ₹15.00 Cr
- product pipeline
- 150.0 SKUs
Sai Parenterals Other Announcement
Sai Parenterals Ltd submitted the Monitoring Agency Report for the quarter ended 30th June 2026 regarding the utilization of IPO proceeds, as per SEBI regulations.
Sai Parenterals Management Change
Sai Parenterals Limited appointed Mr. Ashwani Singh Bisht as Company Secretary and Mr. Arvind Gannimitta as COO. These appointments follow the resignation of Ms. Shivali Aggarwal.
Sai Parenterals Annual General Meeting
Sai Parenterals held its 25th Annual General Meeting on September 10, 2026. Shareholders approved financial statements, director appointments, and various company resolutions.
Sai Parenterals Bags ₹204 Cr Order
Sai Parenterals' subsidiary, Noumed Pharmaceuticals, renewed a 3-year OTC Medicines Supply Agreement with an Australian pharmacy chain, valued at approximately ₹204 Crore.
- Value
- ₹204.0 Cr
- Execution
- 3 years
Other board meeting outcome announcements
All →R R Kabel Board Meeting Outcome
RR Kabel's board approved amendments to its UPSI fair disclosure code on 28 October 2026. The amended code is enclosed and posted on the company website.
M K Exim (India) Board Meeting Outcome
M.K. Exim (India) approved shifting its registered office within Jaipur to Plot J-1247, Sitapura. The board meeting was held on October 28, 2026.
United Spirits Board Meeting Outcome
United Spirits' board approved amendments to its insider trading code on 28 October 2026, effective 29 October 2026. The revised code is available on the company website.
SBI Funds Management Board Meeting Outcome
SBI Funds Management extended internal auditor Chhajed & Doshi's term to March 31, 2030. This routine decision was taken at the October 28, 2026 board meeting.
- Execution
- April 1, 2028 to March 31, 2030
Paras Healthcare Board Meeting Outcome
Paras Healthcare filed its board-approved UPSI fair disclosure code under Regulation 8(2). This routine governance policy update reports no business event.
Gateway Distriparks Board Meeting Outcome
Gateway Distriparks' board approved a revised Code of Practices for Fair Disclosure of UPSI under PIT Regulation 8(2). This is a routine governance policy update with no business event.